A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.

被引：0
|
作者：
Zhu, Wenyu
Chu, Yunqian
He, Xuan
Jiang, Hua
Zhu, Chan
Zhang, Xing
Wu, Fangfang
Dai, Hanjue
Xian, Qingying
Xue, Ya
机构：
[1] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Oncol, Changzhou, Jiangsu, Peoples R China
[2] Dalian Med Univ, Grad Sch, Dalian, Peoples R China
[3] Jiangsu Simcere Diagnost Co Ltd, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16008
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma
    Chu, Yunqian
    He, Xuan
    Xue, Ya
    Jiang, Hua
    Zhu, Chan
    Qi, Chunjian
    Zhang, Xing
    Chen, Dongsheng
    Dai, Hanjue
    Xian, Qingying
    Zhu, Wenyu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Camrelizumab combined with SOX regimen in the first-line treatment of unresectable advanced or recurrent gastric cancer: A single-arm, prospective, open clinical study.
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
    Liu, Wenlou
    Qin, Xiaobing
    Zhao, Yang
    Ge, Yan
    Tang, Juanjuan
    Wang, Hongmei
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090
  • [4] Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study
    Dai, Y.
    Hong, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S710 - S710
  • [5] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
    Chen, Xiaofeng
    Xu, Hao
    Wang, Deqiang
    Chen, Xiaobing
    Wang, Kangxin
    Jin, Guangfu
    Ding, Yongbin
    Tang, Jie
    Fang, Yueyu
    Sun, Hui
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    Guo, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 365 - 365
  • [6] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [7] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [8] Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose-escalation and expansion study.
    Chen, Xiaofeng
    Ding, Yongbin
    Wang, Deqiang
    Wang, Kangxin
    Xu, Hao
    Tang, Jie
    Li, Wei
    Fang, Yueyu
    Sun, Hui
    Liu, Liang
    Jiang, Qiusheng
    Pan, Lanlan
    Tian, Yitong
    Wang, Rong
    Xu, Tongpeng
    Meng, Lijuan
    Li, Fengyuan
    Shu, Yongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16053 - E16053
  • [9] Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
    He, J.
    Yang, Y.
    Zhou, S.
    Zhang, B.
    Han, Z.
    Wu, T.
    Qiao, Q.
    Yang, H.
    He, X.
    Wang, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1549 - S1549
  • [10] Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.
    Zhao, Yanbin
    Zhang, Minghui
    Liu, Jinglei
    Pu, Haihong
    Li, Yinghong
    Li, Xin
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345